Cassava Sciences, Inc. Common Stock (FLNA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cassava Sciences, Inc. Common Stock (FLNA) trades at $0.9425 with AI Score 29/100 (Grade F). Filana Therapeutics, Inc. is a biotechnology company focused on developing novel drugs and diagnostics for Alzheimer's disease. Market cap: $45.5M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for FLNA: FLNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FLNA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FLNA: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Cassava Sciences, Inc. Common Stock (FLNA) Healthcare & Pipeline Overview
Filana Therapeutics, Inc., a biotechnology firm with a market capitalization of $45.5M, specializes in Alzheimer's disease therapeutics, including PTI-125 and PTI-125Dx. The company, founded in 1998, operates in the high-risk, high-reward biotechnology sector, characterized by extensive research and development and regulatory hurdles.
What Is the Investment Thesis for FLNA?
Filana Therapeutics, with a market cap of $45.5M, presents a high-risk, high-reward investment opportunity centered on its Alzheimer's disease drug candidates, PTI-125 and PTI-125Dx. The company's negative P/E ratio of -1.03 reflects its current lack of profitability, typical for biotech firms in the development stage. Key value drivers include successful clinical trial outcomes for PTI-125 and PTI-125Dx, regulatory approvals, and potential partnerships with larger pharmaceutical companies. Upcoming catalysts include the progression of PTI-125 through clinical trials and the development of PTI-125Dx as a diagnostic tool. Potential risks involve clinical trial failures, regulatory setbacks, and the need for additional capital to fund ongoing research and development.
Based on FMP financials and quantitative analysis
FLNA Key Highlights
Market capitalization of $45.5M, placing it in the small-cap biotechnology segment.
- Focus on Alzheimer's disease therapeutics, addressing a significant unmet medical need.
- Lead product candidates PTI-125 and PTI-125Dx are in the development stage.
- P/E ratio of -1.03, indicative of a company currently not generating profit.
- Beta of -0.84, suggesting a lower volatility compared to the overall market.
Who Are FLNA's Competitors?
FLNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FLNA's Key Strengths?
Focus on Alzheimer's disease, a significant unmet medical need.
- Proprietary drug candidates (PTI-125 and PTI-125Dx).
- Experienced management team.
- Dedicated research and development efforts.
What Are FLNA's Weaknesses?
Limited financial resources compared to larger pharmaceutical companies.
- Dependence on successful clinical trial outcomes.
- High regulatory risk.
- Small team size (20 employees).
What Could Drive FLNA Stock Higher?
Clinical trial results for PTI-125 in Alzheimer's disease.
- Regulatory submissions for PTI-125 and PTI-125Dx.
- Development of PTI-125Dx as a diagnostic tool.
- Exploration of strategic partnerships with pharmaceutical companies.
What Are the Key Risks for FLNA?
Financial-distress signal — its Altman Z-Score of -7.15 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-99.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for PTI-125.
- Regulatory setbacks or delays.
- Competition from other companies developing Alzheimer's drugs.
- Need for additional capital to fund research and development.
- Negative beta of -0.84, which may indicate unusual behavior relative to the market.
What Are the Growth Opportunities for FLNA?
- Expansion of PTI-125's clinical applications: Filana Therapeutics can explore the potential of PTI-125 beyond Alzheimer's disease, investigating its efficacy in treating other neurodegenerative disorders. The market for neurodegenerative disease therapeutics is projected to reach $45 billion by 2028, presenting a substantial growth opportunity. This expansion would require additional clinical trials and research, potentially extending the timeline by 3-5 years.
- Development of novel diagnostic tools: Filana can capitalize on the growing demand for early and accurate Alzheimer's disease diagnostics by further developing PTI-125Dx. The Alzheimer's diagnostics market is expected to reach $9.6 billion by 2027. Successful development and commercialization of PTI-125Dx could provide a significant revenue stream within the next 2-3 years.
- Strategic partnerships and collaborations: Collaborating with larger pharmaceutical companies for clinical trials, manufacturing, and distribution can accelerate the development and commercialization of Filana's drug candidates. Such partnerships can provide access to funding, expertise, and established market channels, potentially leading to faster market penetration within 3-5 years.
- Geographic expansion: Expanding clinical trials and eventual commercialization efforts to international markets, particularly in regions with aging populations and high Alzheimer's prevalence, can significantly increase Filana's market reach. This expansion could target Europe and Asia, where the demand for Alzheimer's treatments is rapidly growing, with potential market entry within 5-7 years.
- Personalized medicine approach: Tailoring treatment strategies based on individual patient characteristics and genetic profiles can improve the efficacy of PTI-125. This personalized medicine approach requires further research into biomarkers and genetic factors associated with Alzheimer's disease, potentially leading to more effective and targeted therapies within the next 5-7 years.
What Are FLNA's Competitive Advantages?
- Proprietary drug candidates (PTI-125 and PTI-125Dx).
- Intellectual property protection through patents.
- Focus on a specific therapeutic area (Alzheimer's disease).
- Expertise in neurodegenerative disease research.
What Does FLNA Do?
Filana Therapeutics, Inc., established in May 1998 by Remi Barbier, is a biotechnology company headquartered in Austin, Texas. The company is dedicated to the discovery and development of innovative drugs and diagnostics, with a primary focus on addressing Alzheimer's disease. Their leading product candidates, PTI-125 and PTI-125Dx, represent the core of their therapeutic pipeline. PTI-125 is being developed as a potential treatment for the underlying causes of Alzheimer's, while PTI-125Dx is intended as a diagnostic tool to aid in early detection and monitoring of the disease. Filana Therapeutics operates within the highly competitive and regulated biotechnology industry, requiring significant investment in research and clinical trials. The company's success hinges on the successful completion of these trials and subsequent regulatory approvals from agencies such as the FDA. With a team of 20 employees, Filana is considered a small-cap player in the biotech space, necessitating strategic partnerships and efficient resource allocation to advance its drug development programs. The company's focus on Alzheimer's disease positions it within a critical area of unmet medical need, given the growing global prevalence of the condition and the limited availability of effective treatments.
What Products and Services Does FLNA Offer?
- Develop novel drugs for Alzheimer's disease.
- Create diagnostic tools for early detection of Alzheimer's.
- Conduct research and clinical trials to evaluate drug candidates.
- Seek regulatory approvals for new drugs and diagnostics.
- Explore strategic partnerships for development and commercialization.
- Focus on addressing unmet medical needs in neurodegenerative diseases.
How Does FLNA Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through drug sales and licensing agreements.
- Fund research and development through venture capital and grants.
- Potentially generate revenue from diagnostic testing services.
What Industry Does FLNA Operate In?
Filana Therapeutics operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory scrutiny, and significant investment requirements. The Alzheimer's disease therapeutics market is a major area of focus, driven by the increasing global prevalence of the disease and the limited availability of effective treatments. Competition includes major pharmaceutical companies and other biotech firms also developing Alzheimer's drugs. Success in this market requires strong scientific innovation, successful clinical trials, and strategic partnerships to navigate the complex regulatory landscape and commercialization challenges.
Who Are FLNA's Key Customers?
- Patients suffering from Alzheimer's disease.
- Healthcare providers and physicians.
- Hospitals and clinics.
- Pharmaceutical companies (potential partners).
Key Financial Metrics
Return on equity for Cassava Sciences, Inc. Common Stock stands at -99.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -71.9%, showing how much profit it generates from its asset base. A current ratio of 2.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -135.5%, the inverse of the P/E and a quick read on earnings relative to price.
Cassava Sciences, Inc. Common Stock (FLNA) Valuation Context
Valued at $45.5M, FLNA is classified as a micro-cap stock. Relative to its peer group, FLNA's quantitative score of 29/100 is below the peer average of 76/100.
Company Profile
Cassava Sciences, Inc. Common Stock operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Richard Jon Barry. FLNA has traded publicly since 2000.
Financial Health
Cassava Sciences, Inc. Common Stock's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.15 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Cassava Sciences, Inc. Common Stock has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 27.7% above estimates on average.
Forward Outlook
Wall Street analysts project Cassava Sciences, Inc. Common Stock revenue of about $0 for fiscal 2026, with EPS near $-0.90.
FLNA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on Alzheimer's disease, a significant unmet medical need.
- Proprietary drug candidates (PTI-125 and PTI-125Dx).
- Experienced management team.
- Dedicated research and development efforts.
Bear Case
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on successful clinical trial outcomes.
- High regulatory risk.
- Small team size (20 employees).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
FLNA Latest News
No recent news available for FLNA.
FLNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FLNA.
Price Targets
Wall Street price target analysis for FLNA.
FLNA MoonshotScore
What does this score mean?
The MoonshotScore rates FLNA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Richard Jon Barry
Managing
Richard Jon Barry is the managing person at Filana Therapeutics, overseeing a team of 20 employees. Information regarding his specific background, career history, education, and previous roles is not available in the provided data. Further research would be needed to provide a comprehensive profile.
Track Record: Due to the limited information available, Richard Jon Barry's specific achievements, strategic decisions, and company milestones under his leadership cannot be assessed. Additional data sources would be required to evaluate his track record.
Cassava Sciences, Inc. Common Stock Healthcare Stock: Key Questions Answered
What does the AI Score mean for FLNA?
FLNA holds an AI Score of 29/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Filana Therapeutics, Inc. is a biotechnology company focused on developing novel drugs and diagnostics for Alzheimer's disease. Their lead product candidates include PTI-125 and PTI-125Dx.
What does Filana Therapeutics, Inc. do?
Filana Therapeutics, Inc. is a biotechnology company focused on developing novel drugs and diagnostics for Alzheimer's disease. Their primary focus is on their lead product candidates, PTI-125, a potential treatment for the underlying causes of Alzheimer's, and PTI-125Dx, a diagnostic tool for early detection and monitoring. The company operates within the high-risk, high-reward biotechnology sector, requiring significant investment in research and clinical trials to bring these products to market.
What are the main risks for FLNA?
The primary risks for Filana Therapeutics include the potential for clinical trial failures, regulatory setbacks, and the need for additional capital to fund ongoing research and development. As a small-cap biotechnology company, Filana faces intense competition from larger pharmaceutical companies with greater resources. The success of Filana hinges on the successful completion of clinical trials and subsequent regulatory approvals for PTI-125 and PTI-125Dx.
What are the key factors to evaluate for FLNA?
Cassava Sciences, Inc. Common Stock (FLNA) holds an AI score of 29/100 (low). Filana Therapeutics, with a market cap of $45.5M, presents a high-risk, high-reward investment opportunity centered on its Alzheimer's disease drug candidates, PTI-125 and PTI-125Dx. Not financial advice.
How frequently does FLNA data refresh on this page?
FLNA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven FLNA's recent stock price performance?
Cassava Sciences, Inc. Common Stock (FLNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on Alzheimer's disease, a significant unmet medical need. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FLNA overvalued or undervalued right now?
Cassava Sciences, Inc. Common Stock (FLNA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research FLNA before investing?
Before investing in Cassava Sciences, Inc. Common Stock (FLNA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding FLNA to a portfolio?
Key strength of Cassava Sciences, Inc. Common Stock (FLNA): Focus on Alzheimer's disease, a significant unmet medical need. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data provided.
- AI analysis is pending, which may provide further insights.
- The biotechnology industry is inherently risky and subject to regulatory changes.